|
1) Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell. 2004; 116: 337-50
|
|
|
|
2) Minokoshi Y, Kahn CR, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J Biol Chem. 2003; 278: 33609-12
|
|
|
|
|
|
3) Kitamura T, Kahn CR, Accili D. Insulin receptor konckout mice. Annu Rev Physiol. 2003; 65: 313-32
|
|
|
|
|
|
4) Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skelton. Cell. 2007; 130: 456-69
|
|
|
|
|
|
5) Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003; 111: 737-47
|
|
|
|
|
|
6) Gavrilova O, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem. 2003; 278: 34268-76
|
|
|
|
|
|
7) He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A. 2003; 100: 15712-7
|
|
|
|
|
|
8) Hevener AL, He W, Barak Y, et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med. 2003; 9: 1491-7
|
|
|
|
|
|
9) Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001; 409: 729-33
|
|
|
|
|
|
10) Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBb). Science. 2001; 292: 1728-31
|
|
|
|
|
|
11) Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, et al. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 2001; 291: 2613-6
|
|
|
|
|
|
12) An J, Muoio DM, Shiota M, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2005; 10: 268-74
|
|
|
|
|
|
13) Ishigaki Y, Katagiri H, Yamada T, et al. Dissipating excess energy stored in the liver is a potential therapeutic target for diabetes associated with obesity. Diabetes. 2005; 54: 322-32
|
|
|
|
|
|
14) Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000; 289: 2122-5
|
|
|
|
|
|
15) Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000; 288: 2379-81
|
|
|
|
|
|
16) Obici S, Feng Z, Morgan K, et al. Central administration of oleic acid inhibits glucose production and food intake. Diabetes. 2002; 51: 271-5
|
|
|
|
|
|
17) Obici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med. 2002; 8: 1376-82
|
|
|
|
|
|
18) Lam TK, Pocai A, Gutierrez-Juarez R. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005; 11: 320-7
|
|
|
|
|
|
19) Pocai A, Obici S, Schwartz GJ, et al. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005; 1: 53-61
|
|
|
|
|
|
20) Inoue H, Ogawa W, Asakawa A, et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006; 3: 267-75
|
|
|
|
|
|
21) Lam TK, Gutierrez-Juarez R, Pocai A, et al. Regulation of blood glucose by hypothalamic pyruvate metabolism. Science. 2005; 309: 943-7
|
|
|
|
|
|
22) Lam TK, Gutierrez-Juarez R, Pocai A, et al. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med. 2007; 13: 171-80
|
|
|
|
|
|
23) Caspi L, Wang PY, Lam TK. A balance of lipid-sensing mechanisms in the brain and liver. Cell Metab. 2007; 6: 99-104
|
|
|
|
|
|
24) Yamada T, Katagiri H, Ishigaki Y, et al. Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: Neuronal involvement in food-intake regulation. Cell Metab. 2006; 3: 223-9
|
|
|
|
|
|
25) Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. J Clin Invest. 1997; 100: 2900-8
|
|
|
|
|
|
26) Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000; 106: 1221-8
|
|
|
|
|
|
27) Memon RA, Hotamisligil GS, Wiesbrock SM, et al. Upregulation of uncoupling protein 2 mRNA in genetic obesity: lack of an essential role for leptin, hyperphagia, increased tissue lipid content, and TNF-alpha. Biochim Biophys Acta. 2000; 1484: 41-50
|
|
|
|
|
|
28) Rahimian R, Masih-Khan E, Lo M, et al. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem. 2001; 224: 29-37
|
|
|
|
|
|
29) Nagase I, Yoshida T, Kumamoto K, et al. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. J Clin Invest. 1996; 97: 2898-904
|
|
|
|
|
|
30) Uno K, Katagiri H, Yamada T, et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science. 2007; 312: 1656-9
|
|
|
|
|
|
31) Kreier F, Yilmaz A, Kalsbeek A, et al. Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes. 2003; 52: 2652-6
|
|
|
|
|
|
32) Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science. 2005; 307: 375-9
|
|
|
|
|
|
33) Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Cir Res. 2007; 101: 27-39
|
|
|
|
|